---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019739"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:21:36.235204+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivos Q1 revenue down 10.5% to $3.4M, operating expenses cut 22%; Medicare reimbursement approved for CARE devices

## Summary
- Q1 revenue $3.4M vs $3.8M YoY; gross margin 57% vs 61%.
- Operating expenses down 22% YoY ($1.6M reduction); operating loss reduced 24% YoY.
- Cash $2.6M at March 31; Feb 2024 warrant exercise raised ~$4.0M from 980,393 shares.
- April 2024: received Medicare reimbursement approval for CARE oral devices, enabling coverage for beneficiaries.
- Management targets cash flow positive from operations by end of 2024 or Q1 2025, assuming revenue growth.

## SEC filing metadata
- accession: 0001493152-24-019739
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315224019739/0001493152-24-019739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315224019739/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019739
- JSON: https://secwatch.observer/filing/0001493152-24-019739.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019739.txt

## Key facts
- Earnings Releases
  Vivos Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $3.4 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $3.4 million
  - Result: reported results
  source text: Revenue was $3.4 million for the first quarter of 2024, compared to $3.8 million for the first quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315224019739/0001493152-24-019739-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.